(Good) practice organisational models using real-world evidence for public funding of high priced therapies
Wohlhöfner K, Wild C
Record ID 32018001659
English
Authors' objectives:
The growing market entry of high-cost medicines threatens the financial sustainability of healthcare systems. The limited availability of data on the benefit of therapies at the time of approval poses a challenge for payers. Outcome-based managed-entry agreements (OBMEAs) present a reimbursement tool for payers to fund therapies and enable patient access - under certain conditions. At the same time, new evidence on the effect of treatments in routine practice is collected, which allows the reassessment of therapies at a later point in time. However, data management and ownership often lie with the marketing authorisation holder, which limits information exchange across countries and mutual learning. Therefore, the study aimed to design a generic organisational model for OBMEAs for highly-priced therapies, providing conditional funding while simultaneously generating publicly accessible data on the real-world evidence of treatment effects.
Authors' results and conclusions:
Results: Overall, 16 frameworks were identified, four generic and twelve country-specific models. Their modular design varied considerably across countries due to ,e.g., the different stages of development and implementation of OBMEAs. Therapeutic areas often targeted were oncological and rare diseases, with gene- and CAR-T cell therapies among the most frequently mentioned. Countries reported mixed experiences with OBMEAs, highlighting the burden of data collection and issues with data quality. Following that, recommendations made were to carefully pre-specify data collection, use existing data infrastructure systems, and increase stakeholder engagement and public transparency.
Conclusion: In theory, OBMEAs present an alternative pricing approach by sharing risks equally between private and public entities. Yet, an imbalance is caused by the lack of transparency around these agreements, hindering the successful implementation in practice. Therefore, a higher level of standardisation could generate more comparable results and facilitate cross border information sharing. Existing collaboration initiatives provide a good starting point to achieve public value.
Authors' methods:
A systematic literature search was conducted to identify role models for the organisation of OBMEAs in different countries, followed by eleven semi-structured expert interviews to learn about their experiences made under these schemes.
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://eprints.aihta.at/1329/1/HTA-Projektbericht_Nr.138%20.pdf
URL for additional information:
https://eprints.aihta.at/1329/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Austria
MeSH Terms
- Genetic Therapy
- Health Care Costs
- Bioethics
- Reimbursement Mechanisms
- Models, Organizational
- Technology, High-Cost
- Costs and Cost Analysis
Keywords
- Managed-Entry-Agreements (MEA)
- conditional coverage
- high-priced medicines
- high-priced therapies
- gene therapy
- Advanced Therapy Medicinal Products (ATMP)
Contact
Organisation Name:
Austrian Institute for Health Technology Assessment
Contact Address:
Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name:
office@aihta.at
Contact Email:
office@aihta.at
Copyright:
HTA Austria - AIHTA GmbH
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.